SCHEMBL31408249

SCHEMBL31408249

CC(=O)NCc1cc2cc(Cl)c(-c3cnc(CO)cn3)cc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MTNR1A P48039 5/20 0.35
▸ MTNR1B P49286 4/20 0.35
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HTT P42858 1/20 0.32
▸ RAB9A P51151 2/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ PTGES O14684 2/20 0.31
▸ NPC1 O15118 1/20 0.30
▸ ATR Q13535 1/20 0.30
▸ HSP90AA1 P07900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408395 0.92 SMN1; SMN2 (0.38) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408570 0.87 SMN1; SMN2 (0.39) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408403 0.87 SMN1; SMN2 (0.37) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408309 0.87 SMN1; SMN2 (0.37) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408562 0.86 SMN1; SMN2 (0.38) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408394 0.85 SMN1; SMN2 (0.38) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408238 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408302 0.84 SMN1; SMN2 (0.37) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408457 0.84 SMN1; SMN2 (0.42) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1
SCHEMBL31408346 0.84 SMN1; SMN2 (0.36) SMN1; SMN2MTNR1AMTNR1BMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback